查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014340

持續殘餘療法市場：按產品類型、治療方法、應用和最終用戶分類－2026-2032年全球市場預測

Continuous Renal Replacement Therapy Market by Product Type, Modality, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，連續性腎臟替代療法 (CRRT) 市場價值將達到 167.5 億美元，到 2026 年將成長至 181.3 億美元，到 2032 年將達到 304.3 億美元，複合年成長率為 8.89%。

主要市場統計數據
基準年 2025 167.5億美元
預計年份：2026年 181.3億美元
預測年份 2032 304.3億美元
複合年成長率 (%) 8.89%

持續腎臟替代療法的實施應重點關注臨床需求、營運挑戰和影響相關人員決策的策略重點。

隨著臨床適應症的不斷擴大以及對體液、溶質和血流動力學穩定性進行精準管理的需求日益成長，連續性腎臟替代療法（CRRT）已成為重症腎臟病治療方法的基石。過去十年間，CRRT已從僅限於特定加護病房的專科治療方法發展成為被各類醫院廣泛採用的主流重症治療方法，並在腎臟病學、重症監護和急診管理之間建立了新的聯繫。本文不僅將CRRT定位為一項生命維持技術，更將其視為耗材、監測和治療方法整合領域創新發展的平台。

臨床實踐、技術和營運方面的變革性變化正在將持續腎臟替代療法重塑為以數據驅動、以患者為中心、一體化的護理路徑。

在臨床創新、材料科學進步以及醫療保健系統優先事項轉變的推動下，連續性腎臟替代療法（CRRT）領域正經歷著一場變革。新型膜技術和輸注管理系統正在改善溶質清除率和血流動力學耐受性，而數位化介面和遠端監測工具則使得在不同的醫療環境中實現更一致的治療成為可能。因此，醫療設備生態系統正從獨立的單功能設備演變為集治療、資料收集和決策支援於一體的整合平台。

評估 2025 年美國關稅變化對持續性腎臟替代療法 (CRRT) 的採購、供應鏈韌性和策略採購決策的累積影響。

美國將於2025年實施新的關稅政策，將進一步增加CRRT相關產品的採購和供應策略的複雜性。關稅調整會影響進口組件、組裝依賴型系統以及通常從全球供應商採購的各種耗材。醫療系統採購團隊必須權衡臨床需求與關稅和供應鏈路線變化可能導致的成本波動。

關鍵細分洞察顯示了產品類型、模式、臨床應用和最終用戶環境如何結合起來決定臨床優先事項和籌資策略。

精細的市場細分分析揭示了不同產品類型、治療模式、臨床應用和終端用戶環境如何相互作用，從而影響臨床實踐和採購重點。基於產品類型，市場細分為CRRT配件、CRRT耗材和CRRT系統，每種產品都有獨特的臨床和操作考量。配件便於安裝和感染控制，耗材決定每次治療的成本和供應的連續性，而系統則決定治療能力和互通性。基於治療模式，市場被細分為血液透析濾過、血液透析、血液濾過和超過濾，治療模式的選擇反映了不同患者群體在溶質清除率、液體清除精度和血流動力學接受度之間的權衡。

關鍵區域洞察揭示了美洲、歐洲、中東和非洲以及亞太地區的趨勢如何影響採用、供應鏈策略和監管參與。

區域趨勢對CRRT技術的應用模式、報銷架構和供應鏈選擇有顯著影響。在美洲，臨床網路和三級醫療中心致力於整合診療路徑並投資培訓，以支援先進的CRRT專案；而採購部門則優先考慮合約穩定性和庫存管理，以降低關稅造成的成本波動。歐洲、中東和非洲（EMEA）地區的情況則較為複雜，監管協調和多樣化的報銷機製造就了不同的市場准入路徑。一些市場優先考慮與本地製造商建立夥伴關係以應對進口限制，而另一些市場則優先考慮循證醫學證據的積累，以支持三級醫療中心採用CRRT技術。

關鍵的企業級洞察，展示了創新、供應鏈敏捷性和證據生成如何塑造整個 CRRT 生態系統的競爭差異化。

CRRT領域的競爭活動主要體現在兩個面向：產品漸進式改善和平台差異化。成熟的醫療設備製造商不斷改進泵浦、過濾器和介面，以提高安全性和易用性。同時，新興企業和組件專家正在推出新型薄膜、抗凝血技術和數位化工具，以支持臨床決策。隨著企業拓展至鄰近治療領域、確保耗材供應鏈或整合數據分析能力，策略聯盟、授權協議和選擇性併購日益受到關注。

為產業領導者提供可操作的策略建議，以協調持續腎臟替代療法的臨床價值、價值鏈韌性和市場進入。

行業領導者應優先考慮一系列切實可行的策略，將臨床價值與營運韌性和市場進入相結合。首先，投資於互通性和以用戶為中心的設計，將透過減輕重症監護團隊的認知和時間負擔，並實現與電子健康記錄和數據平台的無縫整合，從而加速產品應用。其次，建立區域製造地和建構戰略經銷夥伴，將降低關稅風險並增強供應連續性，尤其對於常用耗材和一次性配件。第三，發展以結果為導向的證據包，將醫療設備的選擇和治療方案與具有臨床意義的終點聯繫起來，將有助於與保險公司和醫院採購委員會合作。

為了確保分析的穩健性，我們採用了嚴格的跨學科調查方法，結合了初步臨床訪談、二次文獻綜述和跨學科檢驗。

本調查方法採用跨學科方法，結合一手質性研究、二手文獻整合和跨部門檢驗，以全面了解CRRT的現況。主要資訊來源包括與重症監護和腎臟病專科臨床醫生、供應鏈和採購經理、監管專家以及醫療設備和耗材製造商的高級管理人員進行的結構化訪談和討論。這些對話提供了公開資訊來源無法完全涵蓋的治療利用模式、採購決策者和營運限制等方面的背景資訊。

整合臨床、營運和政策見解，為 CRRT 解決方案的可操作決策和策略投資提供明確的展望。

總之，連續性腎臟替代療法（CRRT）在現代重症監護中發揮著至關重要的作用，其發展受到快速的臨床創新、不斷變化的採購趨勢以及不同地區政策環境的影響。產品層面的創新、治療方法的選擇以及特定應用的需求相互作用，為製造商和醫療系統創造了大量機會，以改善患者預後和提升營運效率。同時，價格波動和供應鏈的脆弱性凸顯了策略性採購和立足本地的韌性對於確保持續獲得​​維持生命治療的重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：持續殘餘療法市場：依產品類型分類

  • CRRT配件
  • CRRT耗材
  • 連續性腎臟替代療法系統

第9章：持續殘餘療法市場：依治療方式分類

  • 血液透析濾過
  • 血液透析
  • 血液過濾
  • 超過濾

第10章：持續殘餘療法市場：依應用領域分類

  • 急性腎損傷（AKI）
  • 慢性腎臟病（CKD）
  • 藥物過量和成癮
  • 敗血症和敗血性休克

第11章：持續殘餘療法市場：以最終用戶分類

  • 門診部
  • 醫院
    • 加護病房
    • 腎臟病學

第12章：持續殘餘療法市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：持續殘餘療法市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：持續殘餘療法市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國持續性腎臟替代療法市場

第16章：中國持續性腎臟替代治療市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Anjue Medical Equipment Co., Ltd.
  • Asahi Kasei Medical Co., Ltd.
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Bellco Srl
  • Biolight Co., Ltd.
  • Cytosorbents Corporation
  • Fresenius Medical Care AG & Co. KGaA
  • Full Medical Co., Ltd.
  • Genrui Biotech Co., Ltd.
  • Getinge AB
  • Guangzhou MeCan Medical Limited
  • Infomed SA
  • Jafron Biomedical Co., Ltd.
  • Kawasumi Laboratories, Inc.
  • Medica SpA
  • Medites Pharma Spol sro
  • Medtronic plc
  • Mindray Medical International Limited
  • Nikkiso Co., Ltd.
  • Ningbo David Medical Device Co., Ltd.
  • Outset Medical, Inc.
  • SWS Hemodialysis Care Co., Ltd.
  • Terumo Corporation
  • Toray Medical Co., Ltd.
Product Code: MRR-433AB1DC293A

The Continuous Renal Replacement Therapy Market was valued at USD 16.75 billion in 2025 and is projected to grow to USD 18.13 billion in 2026, with a CAGR of 8.89%, reaching USD 30.43 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 16.75 billion
Estimated Year [2026] USD 18.13 billion
Forecast Year [2032] USD 30.43 billion
CAGR (%) 8.89%

A focused introduction to continuous renal replacement therapy capturing clinical imperatives, operational pressures, and the strategic priorities driving stakeholder decision-making

Continuous renal replacement therapy has emerged as a keystone intervention in critical care nephrology, driven by expanding clinical indications and the need for precision management of fluid, solute, and hemodynamic stability. Over the past decade, CRRT has transitioned from a niche therapy reserved for select intensive care units to a mainstream critical care modality adopted across diverse hospital settings, creating new intersections between nephrology, critical care, and acute care operations. This introduction frames CRRT not only as a life-sustaining technology but also as a platform for innovation in consumables, monitoring, and modality integration.

Clinicians increasingly prioritize therapy personalization, aiming to align modality choices, anticoagulation strategies, and replacement fluid management with patient phenotypes and pathophysiology. Concurrently, health systems are balancing clinical outcomes with supply chain resilience and workforce competency, prompting greater institutional investment in training and standardized protocols. These converging forces underscore the importance of multidimensional analysis that considers clinical efficacy, operational feasibility, and economic sustainability. In the sections that follow, readers will find an integrated perspective on emerging technologies, regulatory influences, tariff impacts, segmentation dynamics, regional trends, competitive activity, and pragmatic recommendations designed to support leaders seeking to optimize CRRT delivery and planning.

Transformational clinical, technological, and operational shifts reshaping continuous renal replacement therapy into integrated data-driven and patient-centric care pathways

The CRRT landscape is undergoing transformative shifts propelled by clinical innovation, material science advances, and changes in health system priorities. New membrane technologies and fluid management systems are improving solute clearance profiles and hemodynamic tolerance, while digital interfaces and remote monitoring tools are enabling more consistent therapy delivery across varied care settings. As a result, device ecosystems are evolving from discrete, single-purpose machines into integrated platforms that combine therapy delivery with data capture and decision support.

Adoption patterns are also changing. Critical care teams are re-evaluating modality selection with a stronger emphasis on patient-centered criteria and real-world outcomes rather than solely technical specifications. Concurrently, supply chain strategies are shifting toward bundled procurement models that prioritize interoperability and lifecycle management. Regulatory oversight and standards of care are tightening, accelerating the uptake of technologies that demonstrate clear safety and usability benefits. Taken together, these shifts are reshaping competitive dynamics and creating opportunities for companies that can deliver clinically differentiated products, scalable training programs, and robust evidence of improved care processes and outcomes.

Assessing the cumulative impact of United States tariff changes on continuous renal replacement therapy procurement, supply chain resilience, and strategic sourcing decisions for 2025

The introduction of new tariff policies in the United States for 2025 has created an additional layer of complexity in the procurement and supply strategies for CRRT-related goods. Tariff adjustments have implications for imported components, assembly-dependent systems, and a range of consumables that are often sourced from global suppliers. Health system purchasing teams must now reconcile clinical imperatives with potential cost variability introduced by customs duties and supply chain re-routing.

These policy changes are incentivizing a reappraisal of domestic sourcing strategies, supplier diversification, and the negotiation of longer-term agreements to stabilize pricing and availability. Some manufacturers are accelerating regional manufacturing footprints or securing tariff classification reviews to mitigate duty exposure. In parallel, hospitals and group purchasing organizations are exploring hybrid sourcing models that combine local inventory buffers with strategic imports to manage episodic cost fluctuations. The net effect is a heightened emphasis on supply chain transparency, tariff risk assessment, and contract clauses that protect against sudden cost escalations, all while ensuring uninterrupted delivery of life-critical CRRT therapies.

Key segmentation insights demonstrating how product categories, modalities, clinical applications, and end-user settings together determine clinical priorities and procurement strategies

A nuanced segmentation analysis reveals how different product categories, modalities, clinical applications, and end-user settings interact to shape clinical practice and procurement priorities. Based on product type, the market is studied across CRRT Accessories, CRRT Consumables, and CRRT Systems, each presenting distinct clinical and operational considerations: accessories drive ease of set-up and infection control, consumables determine per-treatment economics and supply continuity, and systems define therapy capability and interoperability. Based on modality, the market is studied across Hemodiafiltration, Hemodialysis, Hemofiltration, and Ultrafiltration, with modality selection reflecting trade-offs among solute clearance, fluid removal precision, and hemodynamic tolerance in diverse patient profiles.

Based on application, the market is studied across Acute Kidney Injury (AKI), Chronic Kidney Disease (CKD), Drug Overdose & Poisoning, and Sepsis & Septic Shock, and each application imposes unique demands on session duration, anticoagulation protocols, and monitoring intensity. Based on end user, the market is studied across Ambulatory Care Centers and Hospitals, with the Hospitals segment further examined across Intensive Care Units and Nephrology Departments, highlighting differences in capital allocation, staffing competencies, and clinical governance. Synthesizing these dimensions clarifies where innovation will deliver the greatest clinical value and where procurement leaders should prioritize interoperability, consumable standardization, and staff training to reduce variability in outcomes and total cost of care.

Critical regional insights revealing how Americas, Europe Middle East & Africa, and Asia-Pacific dynamics shape adoption, supply chain strategy, and regulatory engagement

Regional dynamics materially influence adoption patterns, reimbursement frameworks, and supply chain options for CRRT technologies. In the Americas, clinical networks and tertiary care centers are focusing on consolidation of care pathways and investment in training to support advanced CRRT programs, while procurement groups emphasize contract stability and inventory management to mitigate tariff-driven cost volatility. Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization and reimbursement variability create differentiated pathways for market entry, with some markets favoring local manufacturing partnerships to address import constraints and others prioritizing evidence generation to support adoption in tertiary centers.

Asia-Pacific features a mix of rapid capacity expansion and targeted technology adoption; growth is often concentrated in urban tertiary institutions that serve as hubs for clinical trials and protocol development. Across regions, cross-border partnerships, technology transfer agreements, and regional distribution strategies are becoming more important as manufacturers seek to align manufacturing footprints with demand centers and regulatory requirements. These regional contrasts underscore the need for tailored market approaches that reflect local clinical priorities, supply chain realities, and policy environments, while maintaining global standards of care and product quality.

Key company-level insights showing how innovation, supply chain agility, and evidence generation are shaping competitive differentiation across the CRRT ecosystem

Competitive activity in the CRRT field is characterized by a dual focus on incremental product improvements and platform-level differentiation. Established device manufacturers continue to refine pumps, filters, and interfaces to improve safety and usability, while emerging firms and component specialists are introducing novel membranes, anticoagulation technologies, and digital tools that augment clinical decision-making. Strategic collaborations, licensing arrangements, and selective M&A are notable as companies seek to expand into adjacent therapy areas, secure consumable supply chains, or integrate data analytics capabilities.

In response to clinical demand for reduced variability and improved outcomes, many organizations are investing in evidence generation programs that include usability studies, real-world data collection, and outcome-based partnerships with health systems. Supply chain resilience has become a competitive axis, with leaders differentiating through localized production, multi-sourcing strategies, and transparent traceability. Commercial models are also evolving, with subscription and service-oriented arrangements gaining traction among buyers who prioritize predictable lifecycle costs and integrated training and maintenance services. These dynamics favor companies with balanced portfolios that combine durable system-level offerings with modular consumable ecosystems and robust post-sale support.

Actionable strategic recommendations for industry leaders to align clinical value, supply chain resilience, and market access in continuous renal replacement therapy

Industry leaders should prioritize a set of actionable strategies that align clinical value with operational resilience and market access. First, investing in interoperability and user-centered design will accelerate adoption by reducing cognitive and time burdens on critical care teams and enabling seamless integration with electronic health records and data platforms. Second, establishing regional manufacturing or strategic distribution partnerships will mitigate tariff exposure and strengthen supply continuity, particularly for high-use consumables and single-use accessories. Third, developing outcome-focused evidence packages that link device choices and modality protocols to clinically meaningful endpoints will facilitate engagement with payers and hospital procurement committees.

Leaders should also adopt flexible commercial models that combine capital, consumable, and service elements to accommodate the diverse payment and procurement environments across regions. Finally, prioritizing clinician training programs and competency-assessment frameworks will reduce therapy variability and enhance perceived value among end users. By operationalizing these recommendations through coordinated R&D, commercial, and regulatory actions, companies can create defensible positions that respond to both clinical demands and evolving policy constraints.

A rigorous multidisciplinary research methodology combining primary clinical interviews, secondary literature review, and cross-functional validation to ensure analytic robustness

The research methodology integrates a multidisciplinary approach combining primary qualitative inquiry, secondary literature synthesis, and cross-functional validation to achieve a comprehensive view of the CRRT landscape. Primary inputs included structured interviews and consultations with clinicians specializing in critical care and nephrology, supply chain and procurement leaders, regulatory experts, and senior executives from device and consumable manufacturers. These engagements provided contextual insights into therapy use patterns, procurement decision drivers, and operational constraints that are not fully captured in publicly available sources.

Secondary research encompassed peer-reviewed clinical literature, regulatory guidance documents, device labeling information, and industry publications to triangulate clinical efficacy, safety considerations, and technology capabilities. The analysis applied a segmentation framework that layered product type, modality, application, and end-user perspectives to identify areas of unmet clinical need and commercial opportunity. Synthesis and validation steps included expert review cycles and scenario testing to ensure findings are robust across different clinical settings and regional policy environments. Where appropriate, sensitivity checks and cross-references were used to reconcile divergent perspectives and strengthen the interpretability of conclusions.

Concluding perspective synthesizing clinical, operational, and policy insights to guide pragmatic decision-making and strategic investment in CRRT solutions

In summary, continuous renal replacement therapy occupies a pivotal role in modern critical care, shaped by rapid clinical innovation, evolving procurement dynamics, and regionally differentiated policy environments. The interplay between product-level innovation, modality selection, and application-specific requirements creates rich opportunities for manufacturers and health systems to enhance patient outcomes and operational efficiency. At the same time, tariff changes and supply chain vulnerabilities underscore the need for strategic sourcing and localized resilience to ensure continuous access to life-critical therapies.

Decision-makers should approach CRRT strategy with a holistic lens that balances clinical evidence, clinician usability, supply chain integrity, and flexible commercial models. By aligning R&D investments with real-world clinical needs and by strengthening partnerships across the care continuum, stakeholders can reduce variability in care delivery and create sustainable value. The integrated insights presented here are intended to support clinical leaders, procurement officers, and commercial strategists as they navigate competing priorities and implement pragmatic solutions that improve both patient outcomes and organizational performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Continuous Renal Replacement Therapy Market, by Product Type

  • 8.1. CRRT Accessories
  • 8.2. CRRT Consumables
  • 8.3. CRRT Systems

9. Continuous Renal Replacement Therapy Market, by Modality

  • 9.1. Hemodiafiltration
  • 9.2. Hemodialysis
  • 9.3. Hemofiltration
  • 9.4. Ultrafiltration

10. Continuous Renal Replacement Therapy Market, by Application

  • 10.1. Acute Kidney Injury (AKI)
  • 10.2. Chronic Kidney Disease (CKD)
  • 10.3. Drug Overdose & Poisoning
  • 10.4. Sepsis & Septic Shock

11. Continuous Renal Replacement Therapy Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Hospitals
    • 11.2.1. Intensive Care Units
    • 11.2.2. Nephrology Departments

12. Continuous Renal Replacement Therapy Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Continuous Renal Replacement Therapy Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Continuous Renal Replacement Therapy Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Continuous Renal Replacement Therapy Market

16. China Continuous Renal Replacement Therapy Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Anjue Medical Equipment Co., Ltd.
  • 17.6. Asahi Kasei Medical Co., Ltd.
  • 17.7. B. Braun Melsungen AG
  • 17.8. Baxter International Inc.
  • 17.9. Bellco S.r.l.
  • 17.10. Biolight Co., Ltd.
  • 17.11. Cytosorbents Corporation
  • 17.12. Fresenius Medical Care AG & Co. KGaA
  • 17.13. Full Medical Co., Ltd.
  • 17.14. Genrui Biotech Co., Ltd.
  • 17.15. Getinge AB
  • 17.16. Guangzhou MeCan Medical Limited
  • 17.17. Infomed SA
  • 17.18. Jafron Biomedical Co., Ltd.
  • 17.19. Kawasumi Laboratories, Inc.
  • 17.20. Medica S.p.A.
  • 17.21. Medites Pharma Spol s.r.o.
  • 17.22. Medtronic plc
  • 17.23. Mindray Medical International Limited
  • 17.24. Nikkiso Co., Ltd.
  • 17.25. Ningbo David Medical Device Co., Ltd.
  • 17.26. Outset Medical, Inc.
  • 17.27. SWS Hemodialysis Care Co., Ltd.
  • 17.28. Terumo Corporation
  • 17.29. Toray Medical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY CRRT ACCESSORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY CRRT ACCESSORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY CRRT ACCESSORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY CRRT CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY CRRT CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY CRRT CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY CRRT SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY CRRT SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY CRRT SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HEMODIAFILTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HEMODIAFILTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HEMODIAFILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HEMODIALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HEMODIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HEMODIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HEMOFILTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HEMOFILTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HEMOFILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY ULTRAFILTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY ULTRAFILTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY ULTRAFILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY ACUTE KIDNEY INJURY (AKI), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY ACUTE KIDNEY INJURY (AKI), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY ACUTE KIDNEY INJURY (AKI), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY CHRONIC KIDNEY DISEASE (CKD), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY CHRONIC KIDNEY DISEASE (CKD), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY CHRONIC KIDNEY DISEASE (CKD), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY DRUG OVERDOSE & POISONING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY DRUG OVERDOSE & POISONING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY DRUG OVERDOSE & POISONING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY SEPSIS & SEPTIC SHOCK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY SEPSIS & SEPTIC SHOCK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY SEPSIS & SEPTIC SHOCK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY INTENSIVE CARE UNITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY INTENSIVE CARE UNITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY INTENSIVE CARE UNITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY NEPHROLOGY DEPARTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY NEPHROLOGY DEPARTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY NEPHROLOGY DEPARTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 108. GCC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GCC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. GCC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 111. GCC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. GCC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. GCC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 126. G7 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. G7 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. G7 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 129. G7 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. G7 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. G7 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 132. NATO CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. NATO CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. NATO CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 135. NATO CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. NATO CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. NATO CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)